New insights on genetics of malignant melanoma;Najnovije spoznaje o genskoj osnovi melanoma

Lijecnicki Vjesnik

Volumn 127, Issue 3-4, 2005, Pages 89-93

  Žigmund, Martina ^a   Nikuševa Martić, Tamara ^b   Čačić, Mirjana ^c   Pećina Šlaus, Nives ^b  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c KBC Zagreb   (Croatia)

Author keywords

Melanoma genetics; Skin neoplasms genetics

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE 4; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

CANCER GROWTH; CDKN2A GENE; CHROMOSOME 12Q; CHROMOSOME 16Q; CHROMOSOME 9P; GENE LOCATION; HEREDITY; HUMAN; MELANOMA; ONCOGENE; ONCOGENE RAS; REVIEW; SIGNAL TRANSDUCTION;

HUMANS; MELANOMA; MUTATION; SKIN NEOPLASMS;

EID: 24044490617     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Norris W. A case of fungoid disease. Edinburg Medicine and Surgery 1820;16:562-5.
2. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
3. Guilford P. E-cadherin downregulation in cancer: fuel on the fire? Mol Med Today 1999;5:172-7.
4. McGary EC, Lev DC, Bar-Eli M. Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther 2002;1:459-65.
5. Pećina-Šlaus N. E-cadherin role in normal and malignanat cells. Cancer Cell International 2003;3:17. [http://www.cancerci.com/content/3/ 1/17)].
6. Polsky D, Cordon-Cardo C. Oncogenes in melanoma. Oncogene 2003;22: 3087-91.
7. Pećina-Šlaus N, Gall-Trošelj K, Šlaus M, Radić K, Nikuševa-Martić T, Pavelić K. Genetic changes of the E-cadherin and APC tumour suppressor genes in clear cell renal cell carcinoma. Pathology 2004;36:145-51.
8. Piepkorn M. Genetic and molecular pathology of melanoma. U: Barnhill RL, Piepkorn M, Busam KJ, ur. Pathology of melanocytic nevi and malignant melanoma. New York: Springer; 2004, str. 20-36.
9. Oberman B, Ljubešić N. Elektronska mikroskopska istraživanja melanotičnog i amelanotičnog melanoma hrčka. Liječ Vjesn 1969;91:947-53.
10. Albino AP, Shea CR, McNutt NS. Oncogenes in melanomas. J Dermatol 1992;19:853-67.
11. Newton Bishop JA. Molecular pathology of melanoma. Cancer Metastasis Rev 1997;16:141-54.
12. Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nature Rev 2003;3:559-70.
13. Armstrong, BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001;63:8-18.
14. Boni R, Schuster C, Nehrhoff B, Burg G. Epidemiology of skin cancer. Neuroendrocrinology Lett 2002;2:48-51.
15. Basset-Seguin N, Dereure O, Guillot B. Genetic bases of cutaneous tumors. Ann Dermatol Venereol 1995;122:217-25.
16. Fountain JW, Bale SJ, Housman DE, Dracopoli NC. Genetics of melanoma. Cancer Surv 1990;92:457-62.
17. Kamb A, Shattuck-Eidens D, Eeles R i sur. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet 1994;8:23-6.
18. Zuo L, Weger J, Yang Q i sur. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nature Genet 1996;12:97-9.
19. Stott FJ, Bates S, James MC, McConnell BB. The alternative product from the human CDKN2A locus, p 14(ARF), participates in a regulatory loop with p53 and MDM2. EMBO J 1998;17:5001-14.
20. Sturm RA. Skin colour and skin cancer: MC1R, the genetic link. Melanoma Res 2002;12:405-16.
21. Sieber OM, Tomlison IP, Lamlum H. The adenomatous polyposis coli (APC) tumour suppressor - genetics, function and disease. Mol Med Today 2000;6:462-9.
22. Halachmi S, Gilchrest BA. Update on genetic events in the pathogenesis of melanoma. Curr Opin Oncol 2001;13:129-36.
23. Schaffer JV, Rigel DS, Kopf AW, Bolognia JL. Cutaneous melanoma-past, present, and future. J Am Acad Dermatol 2004;51Suppl 1:65-9.
24. Dong J, Phelps RG, Qiao R i sur. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003;63:3883-5.
25. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK (MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38 (SAPK). Cancer Res 2003;63:1684-95.
26. Spugnardi M, Tommasi S, Dammann R, Pfeifer GP, Hoon DS. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 2003;63:1639-43.
27. Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene 2003;22:3113-22.
28. Trent JM, Rosenfeld SB, Meyskens FL. Chromosome 6q involvement in human malignant melanoma. Cancer Genet Cytogenet 1983;9:177-80.
29. Becher R, Gibas Z, Sandberg AA. Chromosome 6 in malignant melanoma. Cancer Genet Cytogenet 1983;9:173-5.
30. Hussein MR. Genetic pathways to melanoma tumorigenesis. J Clin Pathol 2004;57:797-801.
31. Copeman MC. The putative melanoma tumor-suppressor gene on human chromosome 6q. Pathology 1992;24:307-9.
32. Kamb A, Gruis NA, Weaver-Feldhaus J i sur. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
33. Bogenrieder T, Landthaler M, Stolz W. p16(INK4A)/CDKN2-the »melanoma gene«? Status of research and outlook. Hautarzt 1998;49:91-100.
34. Quelle DE, Zindy F. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
35. Hussussian C. Germline p16 mutations in familial melanoma. Nature Genet 1994;8:15-21.
36. Whiteman DC, Milligan A, Welch J, Green AC, Hayward NK. Germline CDKN2A mutations in childhood melanoma. J Natl Cancer Inst 1997; 89:1460.
37. Aitken J, Welch J, Duffy D i sur. CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst 1999;91:446-52.
38. Levanat S, Šitum M, Crnić I i sur. Alterations in CDKN2A locus as potential indicator of melanoma predisposition in relatives of non-familial melanoma cases. Croat Med J 2003;44:418-24.
39. Piccinin S, Doglioni C, Maestro R i sur. 16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression. Int J Cancer 1997;74:26-30.
40. Kumar R, Sauroja I, Punnonen K, Jansen C, Hemminki K. Selective deletion of exon 1 beta of the p19ARF gene in metastatic melanoma cell lines. Genes Chromosomes Cancer 1998;23:273-7.
41. Rizos H, Puig S, Badenas C i sur. A melanoma-associated germline mutation in exon 1 beta inactivates p14ARF. Oncogene 2001;20:5543-7.
42. Demetrick DJ. Chromosomal mapping of human CDK2, CDK4, and CDK5 cell cycle kinase genes. Cytogenet Cell Genet 1994;66:72-4.
43. Soufir N, Avril MF, Chompret A i sur. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France: the French Familial Melanoma Study Group. Hum Molec Genet 1998;7:209-16.
44. Guldberg P, Kirkin AF, Gronbaek K, thor Straten P, Ahrenkiel V, Zeuthen J. Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: a novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma. J Int J Cancer 1997; 72:780-3.
45. Holland EA, Schmid H, Kefford RF, Mann GJ. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Genes Chromosomes Cancer 1999;25:339-48.
46. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366: 704-7.
47. Sviderskaya EV, Gray-Schopfer VC, Hill SP i sur. p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression. J Natl Cancer Inst 2003;95:723-32.
48. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 1998;95:8292-7.
49. Gantz I, Yamada T, Tashiro T i sur. Mapping of the gene encoding the melanocortin-1 (alpha-melanocyte stimulating hormone) receptor (MC1R) to human chromosome 16q24.3 by fluorescence in situ hybridization. Genomics 1994;19:394-5.
50. Magenis RE, Smith L, Nadeau JH, Johnson KR, Mountjoy KG, Cone RD. Mapping of the ACTH, MSH, and neural (MC3 and MC4) melanocortin receptors in the mouse and human. Mammalian Genome 1994;5:503-8.
51. Valverde P, Healy F, Jackson I, Rees JL, Thody AJ. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nature Genet 1995;11:328-30.
52. Healy E, Flannagan N, Ray A i sur. Melanocortin-1-receptor gene and sun sensitivity in individuals without red hair. Lancet 2000;355:1072-3.
53. Smith R, Healy E, Siddiqui S i sur. Melanocortin 1 receptor variants in an Irish population. J Invest Derm 1998;111:119-22.
54. Flanagan N, Healy E, Ray A i sur. Pleiotropic effects of the melanocortin 1 receptor (MC1R) gene on human pigmentation. Hum Mol Genet 2000;9:2531-7.
55. Palmer JS, Duffy DL, Box NF i sur. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000;66:176-86.
56. Bastiaens M, ter Huurne J, Gruis N i sur. The melanocortin-1-receptor gene is the major freckle gene. Hum Mol Genet 2001;10:1701-8.
57. Box NF, Duffy DL, Chen W i sur. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 2001;69:765-73.
58. Hayward NK. Genetics of melanoma predisposition. Oncogene 2003;22: 3053-62.
59. Dracopoli NC, Fountain JW. CDKN2 mutations in melanoma. Cancer Surv 1996;26:115-32.
60. Cruz J, Reis-Filho JS, Silva P, Lopes JM. Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas. Oncology 2003;65:72-82.
61. Medrano EE. Repression of TGF-beta signaling by the oncogenic protein SKI in human melanomas: consequences for proliferation, survival, and metastasis. Oncogene 2003;22:3123-9.
62. Nyormoi O, Bar-Eli M. Transcriptional regulation of metastasis-related genes in human melanoma. Clin Exp Metastasis 2003;20:251-63.
63. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-2.
64. Jafari M, Papp T, Kirchner S i sur. Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. J Cancer Res Clin Oncol 1995;121:23-30.
65. Bastian BC, Kashani-Sabet M, Hamm H i sur. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res 2000;60:1968-73.
66. Saldanha G, Purnell D, Fletcher A, Potter L, Gillies A, Pringle JH. High BRAF mutation frequency does not characterize all melanocytic tumor types. Int J Cancer 2004;111:705-10.
67. Pollock PM, Harper UL, Hansen KS i sur. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19-20.
68. Bottaro DP, Rubin JS, Faletto DL i sur. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-4
69. Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K, Herlyn M. Downregulation of E-cadherin and desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 2001;20: 8125-35.
70. Natali PG, Nicotra MR, Di Renzo MF i sur. Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. Br J Cancer 1993; 68:746-50.
71. Li J, Yen C, Liaw D i sur. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275:1943-7.
72. Guldberg P, Thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 1997;57:3660-3.
73. Teng DH, Hu R, Lin H i sur. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 1997;57:5221-5.
74. Hoek K, Rimm DL, Williams KR i sur. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 2004;64:5270-82.